CMA1 and Cirrhosis: Chymase inhibitor SF2809E, in this experimental setting, leads to prevention of histological cirrhosis and liver decompensation despite 13 weeks of CCl4 administration, which instead causes ascitic cirrhosis (Figs 1–4) with functional renal failure if chymase is not inhibited.